An experimental treatment happens to be the solution to delay Alzheimer's symptoms in some people. These people are the ones who are genetically destined to get the disease in their 40s or 50s. These new findings form ongoing research has now been caught up in Trump administration funding delas. The early results of the study has been published on Wednesday and the participants too are worried that politics could cut their access to a possible lifeline.

One of the participants had said, "It is still a study but it has given me an extension to my life that I never banked on having." The participant is named Jake Henrichs, form New York City, who is 50 years old. He is one of them to be treated in that study for more than a decade now and has remained symptom-free despite inheriting an Alzheimer's-causing gene that had killed his father and brother around the same age.

Slowing Down The Symptoms

Two drugs which can modestly slow down early-stage Alzheimer's are sold in the United States. These drugs clear the brain of one of its hallmarks, a sticky gunk-like part called the amyloid. However, there have not been any hints that removing amyloid far earlier, way many years before the first symptoms appear, may postpone the disease.

How Was The Research Conducted?

The research is led by Washington University in St Louis, which involved families that passed down rare gene mutation as participants. This meant it was almost guaranteed that they will develop symptoms at the same age their affected relatives did.

The new findings is based on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset. The study is published in the journal Lancet Neurology.

Washington University's Dr Randall Bateman, who directs the Dominantly Inherited Alzheimer's Network of studies involving families with these rare genes says, "What we want to determine over the next five years is how strong is the protection. Will they ever get the symptoms of Alzheimer’s disease if we keep treating them?”

The researchers before though did not know what exactly caused Alzheimer's which affects nearly 7 million Americans, most of them in their later life. However, it is clear that these silent changes occur in the brain at least two decades before the first symptom shows up. The big contributor. At some point amyloid buildup can trigger a protein named tau that then starts to kill neurons, which can lead to cognitive decline.

Researchers are now thus studying the Tau-fighting drugs and are looking into other factors, like inflammation, brain's immune cells and certain virus.

The National Institute of Health (NIH) has expanded its focus as researchers have found more reasons for Alzheimer's. In 2013, the NIH's National Institute on Aging funded 14 trials of possible Alzheimer's drugs over a third targeting amyloid. By last fall, there were 68 drugs and 18% of them target amyloid. However, there are scientists too who think that amyloid is not everything and their is way more in the brain tissue, immune cells, and more which can be studied.

The Supreme Court of India has slammed the steep mark-ups private hospitals charge for cancer medicines, describing excessive pricing as “loot” and “dacoity” as it considers whether tighter regulations are needed to protect patients.

During a hearing on October 27, a bench of Justices Vikram Nath and Sandeep Mehta reserved its verdict on petitions seeking stronger controls on the prices of medicines.

The court highlighted the financial burden faced by people who need life-saving treatment, especially those battling cancer, and questioned whether the government’s current pricing framework protects patients from excessive healthcare costs.

Cancer Injection Costs ₹11,000 But Billed At ₹1.3 lakh

Also read: India Caps Cancer Drug Trade Margins At 30%; Patients May Save Rs 2,500 Crore Annually

The Court was hearing a public interest litigation (PIL) filed by advocate Kishan Chand Jain who sought seeking mandatory generic drug prescriptions, stricter initial price controls on non-scheduled medicines, and statutory margin caps on medical devices under the Drug Price Control Order (DPCO).

One example cited by the court is of a medicine distributor whose wife was undergoing cancer treatment at a prominent private hospital.

According to the account presented during the hearing, the distributor offered to procure a chemotherapy injection at his dealer price of ₹11,000, but the hospital charged ₹1.3 lakh for the same medicine.

“Can you show any justification for this loot, please? Why this difference? Where does the money go?” the bench asked.

The judges also questioned the pricing of routine hospital supplies. A saline drip line with a cost ₹15 was reportedly being billed to patients at ₹250.

These examples raised questions about how medicine procurement costs, manufacturer discounts, hospital operating expenses and final patient bills are accounted for.

The Court also addressed Centre's recent decision to cap trade margins for anti-cancer drugs at 30 percent but how nearly 90 percent of medicines available in the market remain outside the purview of the Drug Price Control Order (DPCO).

"Why is the DPCO in place at all? The government is allowing this to happen. There have been three parliamentary committees on this. And their outcome is not very convenient to people who pull the strings, let us tell you," the Bench remarked.

Medicine Price Caps Under Scrutiny

Also read: 137 Cancer Drugs To Cost Up To 70% Less From November 9: NPPA Caps Trade Margins

India regulates prices of scheduled medicines under the Drugs (Prices Control) Order, 2013. The government has also introduced trade margin limits for a few anti-cancer medicines.

During the hearing, the Centre said trade margins on 137 anti-cancer medicines had been capped at 30% of the maximum retail price (MRP), a measure it estimated could save patients around ₹2,500 crore annually.

The court questioned why such interventions were limited to only a few medicines and whether a bigger and more comprehensive drug regulation was needed.

The petitions seek measures including mandatory generic prescriptions, controls on the initial prices of non-scheduled medicines and limits on trade margins for medical devices.

Hospitals And Government Raise Concerns

Representing private hospitals, senior advocate Mukul Rohatgi argued that healthcare institutions must maintain round-the-clock infrastructure and cover substantial operating costs. He also raised concerns about patients bringing medicines from outside, including the risk of counterfeit products.

The Centre maintained that medicine pricing policy must balance affordability with investment, competition and the sustainability of the pharmaceutical sector.

Additional Solicitor General Aishwarya Bhati told the court that the government continued to review its rules. The bench questioned whether these considerations addressed patients’ limited bargaining power when they need life-saving treatment.

"Your calibration is too wayward. ₹11,000 to ₹1,30,000 is no calibration. When you talk of patients and life, should we have such capitalistic thinking. Hospitals can survive through other means. Not through this dacoity,” the bench remarked, according to reports of the proceedings.

The Supreme Court has reserved its verdict. Until the order is delivered, no new price cap should be assumed. The court’s decision could influence future regulation of medicine prices and hospital mark-ups.

The US Centers for Disease Control and Prevention (CDC) recently released a report that stated drug-resistant infections are causing an estimated 50,800 deaths and 9.7 million infections annually in the United States.

Common bacterial infections are usually treated with antibiotics but some germs develop the ability to resist the medicines designed to fight them. This is a grave threat to public health.

The agency has classified four pathogens as urgent threats, warning that resistance to antibiotics and antifungal medicines is making some infections difficult to treat.

The CDC’s 2026 Antimicrobial Resistance Threats Report, released on October 27, is based on data from 2023. It examines 19 drug-resistant bacterial and fungal threats, categorising them as urgent, serious or concerning based on factors including their effects, spread, preventability and the availability of effective treatments.

“Antimicrobial resistance threatens modern medicine and puts millions of Americans at risk every year,” CDC Director Dr Erica Schwartz said in a statement.

Drug-Resistant Pathogens That Pose The Greatest Risks

The federal health agency has identified the following four pathogens as requiring urgent and aggressive action.

Candida auris

Candida auris, a fungus that can cause severe infections, includes potentially fatal bloodstream infections, particularly in people who are already seriously ill. It is a major concern in hospitals and nursing homes because it can be transmitted through contaminated surfaces and medical equipment like catheters, and some strains resist multiple antifungal medicines.

The CDC recorded 4,523 cases in the United States in 2023. Cases increased by more than 50% between 2022 and 2023, according to the report.

People can carry the fungus on their skin without developing symptoms, allowing it to spread in healthcare environments.

Drug-resistant gonorrhoea

Gonorrhoea is a sexually transmitted infection caused by the bacterium Neisseria gonorrhoeae. The infection can be treated with antibiotics, but the bacterium has developed resistance to several medicines.

The CDC estimates that approximately 787,000 drug-resistant gonorrhoea infections occurred in the US in 2023. Untreated gonorrhoea can cause pelvic inflammatory disease, infertility and other reproductive complications.

The growing resistance leaves healthcare providers with fewer reliable treatment options, making surveillance and the development of new antibiotics important.

Also read: 'It’s The Best-Studied Vaccine In Human History': Former CDC Adviser Busts Common Myths About COVID Vaccines

Carbapenem-resistant Enterobacterales (CRE)

CRE are a group of bacteria, including some strains of Escherichia coli and Klebsiella, that resist carbapenems, a powerful class of antibiotics often reserved for difficult-to-treat infections.

These bacteria can cause infections in the bloodstream, lungs and urinary tract. They pose a particular risk to hospital patients, especially those with weakened immune systems, catheters or ventilators.

In 2023, CRE caused an estimated 14,878 infections among hospitalised patients and 1,252 deaths in the US. Drug resistance can leave doctors with few effective treatment options.

Carbapenem-resistant Acinetobacter

Carbapenem-resistant Acinetobacter is another group of bacteria that can cause serious infections, particularly among critically ill patients in healthcare settings. These include pneumonia, bloodstream infections and infections associated with wounds.

Resistance to carbapenems makes these infections difficult to treat and can increase the risk of complications and death.

Antimicrobial Resistance Is A Growing Concern

The CDC is also monitoring six more kinds of germs. One is drug-resistant ringworm, a fungal skin infection that is becoming harder to treat with standard fungal medications. The health body says misusing over-the-counter antifungal creams and using steroid-antifungal cream combinations may contribute to resistance.

Antimicrobial resistance occurs when bacteria, fungi and other pathogens develop the ability to survive medicines designed to kill them or stop their growth. This can happen through genetic changes and the spread of resistance mechanisms between microbes. The unnecessary or inappropriate use of antimicrobial medicines can accelerate the process.

The consequences extend beyond infections themselves. Drug resistance can prolong hospital stays, increase healthcare costs and make procedures like surgery, cancer treatment and organ transplantation riskier because these depend on effective medicines to treat infections.

Infections commonly associated with healthcare settings accounted for more than 42,000 deaths and nearly $12 billion in US healthcare costs in 2023, according to the report.

The CDC also reported progress in some areas. Clostridioides difficile, a bacterium associated with severe diarrhoea and often linked to antibiotic use, was downgraded from an urgent to a serious threat. The agency attributed the change partly to improvements in infection prevention and antibiotic stewardship.

However, the CDC cautioned that its methods and data sources changed substantially since its previous report. The latest estimates therefore cannot be directly compared with older figures to determine how much the overall burden has increased.

How To Prevent Antibiotic Resistance?

The CDC recommends using antibiotics only when prescribed by a healthcare professional and taking them exactly as directed. Antibiotics do not treat viral infections like the common cold or flu.

Hand hygiene, vaccinations, infection-control measures in healthcare environments including appropriate prescribing practices can also help limit the spread of resistant pathogens.

Joshua, 27, was diagnosed with autism at two and a half. He was nonverbal and experienced severe anxiety, while getting a full night's sleep remained a struggle for years.

An experimental drug called L1-79, touted as ‘Ozempic Of Autism' has reportedly brought significant improvements in his condition, according to the Daily Mail, raising interest in its potential to address core features of autism spectrum disorder (ASD).

How Did The Drug L1-79 Help Joshua?

Developed by Yamo Pharmaceuticals, L1-79 is an oral drug designed to target core symptoms of autism.

Joshua’s psychiatrist of eight years, Dr. Eric Bartky, an autism specialist involved in the US FDA trial of L1-79, asked his parents Linda and Jim Turteltaub to consider trying the drug.

The decision involved uncertainty. Taking part in the trial required Joshua to stop all his other medications, and the potential side effects of the new treatment were not fully known. Despite these concerns, his parents decided in 2015 to give it a try.

“We just wanted something to address the issues, to try and get him better so that he can at least communicate with us,” Linda said.

According to the report, Joshua showed his first notable improvement within a week of beginning treatment.

Also read: Autism Care Begins Early: Why the First 1,000 Days Matter Most, Says AIIMS Expert

How Does L1-79 Work?

Yamo Pharmaceuticals describes L1-79 as a selective inhibitor of tyrosine hydroxylase, an enzyme involved in the production of dopamine and norepinephrine.

The drug is intended to lower the production of these chemical messengers in an effort to regulate pathways that may contribute to sensory overload and social withdrawal in people with autism.

Dr. Bartky said the drug differs from existing approaches because it aims to address core features of autism, including social interaction and communication.

“What makes L1-79 different is that L1-79 treats the core symptoms of autism, things like socialization and communications, things that go along with that like eye contact, reciprocal conversation, nonverbal communication, such as reading social nuance. These are things that are extremely important for a person's emotional growth and functioning in society.”

The response to treatment has varied among Dr. Bartky's patients, reflecting the wide range of symptoms associated with ASD.

What Is The Status Of L1-79 Clinical Trials?

Read More: Stem Cell Therapy For Autism: What India’s New Advisory Means For Patients

There is currently no single medication that treats all the core features of autism spectrum disorder. Several medications are prescribed to manage particular behavioral patterns and associated conditions.

L1-79 is being investigated as a potential treatment that could address autism's underlying neurological features. The Daily Mail reported that 116 patients had participated in L1-79's three clinical trials.

The drug has received Fast Track designation from the US Food and Drug Administration (FDA). This program is intended to facilitate the development and review of treatments for serious conditions that address unmet medical needs.

Although the designation does not shorten the clinical trial process, it can make a drug eligible for priority review. Under this pathway, the FDA aims to complete its review within six months, compared with the standard 10-month timeline.

Are There Any Safety Concerns?

Dr. Bartky also pointed to what he described as L1-79's safety profile.

Some existing medications can cause serious side effects, including dyskinesia, which involves involuntary movements that can sometimes be permanent; metabolic syndrome, a group of conditions associated with increased risks of heart disease, stroke and type 2 diabetes; and hypertension. Dr. Bartky said L1-79 had “not had one single serious side effect.”